CN1081877A - 用荷电树脂的球化方法 - Google Patents

用荷电树脂的球化方法 Download PDF

Info

Publication number
CN1081877A
CN1081877A CN93107621.8A CN93107621A CN1081877A CN 1081877 A CN1081877 A CN 1081877A CN 93107621 A CN93107621 A CN 93107621A CN 1081877 A CN1081877 A CN 1081877A
Authority
CN
China
Prior art keywords
composite particles
spherical composite
production
sodium
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN93107621.8A
Other languages
English (en)
Chinese (zh)
Inventor
G·A·麦克里兰
G·M·曾特纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN1081877A publication Critical patent/CN1081877A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN93107621.8A 1992-06-26 1993-06-25 用荷电树脂的球化方法 Pending CN1081877A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/906,226 US5350584A (en) 1992-06-26 1992-06-26 Spheronization process using charged resins
US906,226 1992-06-26

Publications (1)

Publication Number Publication Date
CN1081877A true CN1081877A (zh) 1994-02-16

Family

ID=25422115

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93107621.8A Pending CN1081877A (zh) 1992-06-26 1993-06-25 用荷电树脂的球化方法

Country Status (9)

Country Link
US (1) US5350584A (enExample)
EP (1) EP0804167A1 (enExample)
JP (1) JP2793042B2 (enExample)
CN (1) CN1081877A (enExample)
AU (1) AU4542393A (enExample)
CA (1) CA2136435A1 (enExample)
TW (1) TW242115B (enExample)
WO (1) WO1994000111A1 (enExample)
YU (1) YU41993A (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107552777A (zh) * 2017-09-05 2018-01-09 昆山玛冀电子有限公司 一种用于电感生产的粉末颗粒成分及生产工艺

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203689D0 (en) * 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
GB9505032D0 (en) * 1995-03-13 1995-05-03 Westminster Lab Ltd Improvements in or relating to organic compositions
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
EP0859600A1 (en) * 1995-11-02 1998-08-26 Merck Frosst Canada Inc. New technology for wet granulation
NZ336225A (en) * 1996-12-12 2001-03-30 Dds Drug Delivery Service Ges Preparation in form of a matrix material-auxiliary agent compound containing optionally an active substance
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
IT1298574B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di microparticelle a base polimerica ottenute mediante estrusione e sferonizzazione
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
DE19855440A1 (de) * 1998-12-01 2000-06-08 Basf Ag Verfahren zum Herstellen fester Darreichungsformen mittels Schmelzextrusion
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
CA2379987A1 (en) * 1999-07-29 2001-02-08 Roxane Laboratories, Inc. Opioid sustained-released formulation
US20030225124A1 (en) * 1999-08-31 2003-12-04 Spiridon Spireas Stable formulations of ACE inhibitors, and methods for preparation thereof
US6555551B1 (en) 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
US20040157911A1 (en) * 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
US6764694B1 (en) * 1999-08-31 2004-07-20 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
DE10008506A1 (de) * 2000-02-24 2001-09-13 Bayer Ag Verfahren zur Herstellung von pharmazeutischen Darreichungsformen
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
PT1274401E (pt) * 2000-04-10 2011-12-02 Teva Pharma Composições farmacêuticas estáveis contendo ácidos 7-substituídos-3,5-di-hidroxi-heptanóicos ou ácidos 7-substituídos-3,5-di-hidroxi-heptenóicos
WO2005041657A1 (en) * 2003-10-20 2005-05-12 Framework Therapeutics, L.L.C. Zeolite molecular sieves for the removal of toxins
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
DE102005042875A1 (de) * 2004-12-23 2006-09-21 Grünenthal GmbH Schnell freisetzende Darreichungsformen für Antibiotika
US8318230B2 (en) * 2005-05-02 2012-11-27 Henkel Ag & Co. Kgaa Use of debranched starch in extrusion-spheronization pharmaceutical pellets
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
WO2010041268A2 (en) * 2008-09-02 2010-04-15 Usv Limited Crosslinked polymers
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
LT2637668T (lt) 2010-11-04 2016-09-12 Albireo Ab Ibat inhibitoriai kepenų ligoms gydyti
US20120308895A1 (en) 2011-05-31 2012-12-06 General Electric Company Electrode compositions useful for energy storage devices and other applications; and related devices and processes
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
JP6830969B2 (ja) * 2016-02-09 2021-02-17 アルビレオ・アクチボラグ コレスチラミンペレット剤及びその調製のための方法
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CA3071182A1 (en) * 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
EP3703724A1 (en) 2017-11-02 2020-09-09 NatureCeuticals Sdn. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
MY209425A (en) 2018-06-20 2025-07-08 Albireo Ab Crystal modifications of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
HRP20230039T1 (hr) 2019-02-06 2023-06-09 Albireo Ab Benzotiadiazepinski spojevi i njihova uporaba kao modulatora žučnih kiselina
CR20220315A (es) 2019-12-04 2022-10-26 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
ES3029063T3 (en) 2019-12-04 2025-06-23 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
ES2973355T3 (es) 2019-12-04 2024-06-19 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CA3198216A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB717840A (en) * 1951-09-22 1954-11-03 Ici Ltd Water-dispersible solid compositions
US3131121A (en) * 1960-10-31 1964-04-28 Hoffmann La Roche Highly acidic cation exchange resin containing amprotropine cations
JPS59500614A (ja) * 1982-04-23 1984-04-12 エイ／エス　アルフレツド　ベンツオン 消化機能調査用の組成物と方法
CA1236023A (en) * 1984-07-18 1988-05-03 Yegnaswami Raghunathan Controlled release pharmaceutical preparations
US4663364A (en) * 1984-09-05 1987-05-05 Kao Corporation Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder
US4976949A (en) * 1985-10-25 1990-12-11 The University Of Michigan Controlled release dosage form
ATE71293T1 (de) * 1986-09-18 1992-01-15 London Pharmacy Innovation Arzneiformulierung.
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
CA2002492A1 (en) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107552777A (zh) * 2017-09-05 2018-01-09 昆山玛冀电子有限公司 一种用于电感生产的粉末颗粒成分及生产工艺

Also Published As

Publication number Publication date
TW242115B (enExample) 1995-03-01
AU4542393A (en) 1994-01-24
JPH07508280A (ja) 1995-09-14
EP0804167A4 (enExample) 1997-11-05
CA2136435A1 (en) 1994-01-06
WO1994000111A1 (en) 1994-01-06
EP0804167A1 (en) 1997-11-05
US5350584A (en) 1994-09-27
JP2793042B2 (ja) 1998-09-03
YU41993A (sh) 1997-01-08

Similar Documents

Publication Publication Date Title
CN1081877A (zh) 用荷电树脂的球化方法
CA1296633C (en) Controlled release bases for pharmaceuticals
EP0785775B2 (en) Melt-extruded orally administrable opioid formulations
CN1081916C (zh) 一种控释药物悬浮液的释放装置
DK1492506T4 (en) Matrix for depot, invariant and independent release of active compounds
US7090867B2 (en) Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
RU2127586C1 (ru) Устройство доставки лекарственного препарата, способ получения устройства
JPH05500668A (ja) 制御放出組成物
EP0851758A1 (en) Pharmaceutical formulation
JPH0772142B2 (ja) 徐放性製剤
JP2000212068A (ja) 薬学的有効物質９０重量％まで含有するペレットの製造方法。
EP2785330B1 (en) Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
BG105325A (bg) Независещи от ефекта на храната многочастичкови фармацевтични препарати за продължително освобождаване и методи за получаването им
JP3134187B2 (ja) 放出制御組成物
JP2000212069A (ja) 有効物質の放出が調節された鎮痛薬
CN1744889A (zh) 坦洛新的控释药物组合物
JP2896355B2 (ja) 持続性動物成長ホルモン製剤およびその製造方法
CN1895233A (zh) 控释活性化合物的药物制剂
JPH09323926A (ja) バルプロ酸ナトリウムの徐放性錠剤
CN101991552A (zh) 他克莫司缓控释制剂及制备方法
CN102008429A (zh) 他克莫司缓控释制剂及其制备方法
EP1667661A1 (en) Extended release formulation of beta-lactam antibiotics
WO1999030671A2 (en) Aspected particles for oral delivery
EP2277511B1 (en) Extended release pharmaceutical compositions of levetiracetam
CN1180779C (zh) 罗红霉素缓释胶囊及制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication